Concomitant Medication Use by Period
| Medication. | Pre-Index Period,N = 1,582 | Post-Index PeriodN = 1,582 | Follow-Up Period,*N = 849 | |
|---|---|---|---|---|
| Insulins | Intermediate-acting | 153 (9.7) | 34 (2.1) | 40 (4.7) |
| Long-acting | 1,205 (76.2) | 251 (15.9) | 279 (32.9) | |
| Premixed | 300 (19.0) | 30 (1.9) | 42 (4.9) | |
| Rapid-acting | 1,076 (68.0) | 185 (11.7) | 235 (27.7) | |
| Short-acting | 122 (7.7) | 28 (1.8) | 46 (5.4) | |
| Any insulin | 1,502 (94.9) | 418 (26.4) | 788 (92.8) | |
| Oral glucose-lowering therapies | DPP-4 inhibitor | 216 (13.7) | 90 (5.7) | 77 (9.1) |
| Metformin | 873 (55.2) | 594 (37.5) | 367 (43.2) | |
| Thiazolidinediones | 190 (12.0) | 68 (4.3) | 47 (5.5) | |
| Sulfonylurea | 375 (23.7) | 111 (7.0) | 72 (8.5) | |
| SGLT2 inhibitor | 3 (0.2) | 21 (1.3) | 38 (4.5) | |
| Any oral glucose-lowering therapies | 1,040 (65.7) | 704 (44.5) | 436 (51.4) | |
| Noninsulin injectable therapy | Pramlintide | 105 (6.6) | 61 (3.9) | 29 (3.4) |
| GLP-1 RA | 172 (10.9) | 90 (5.7) | 56 (6.6) | |
| Any noninsulin injectable | 268 (16.9) | 149 (9.4) | 83 (9.8) | |
Data are n (%). *Patients with gap of ≥60 days in the post-index period. DPP-4, dipeptidyl peptidase-4; GLP-1 RA, glucagon-like peptide 1 receptor agonist.